Late yesterday, the 26th of October, one-time-NaDDiR*-favorite, Amarex, filed its response to the lawsuit (Case 8:21-cv-02533-PJM, see here.) initiated by everybody’s favorite pink sheet reverse-merger Coronacrapper, Cytodyn (CYDY).
Inside the filings are some bombshell documents that The NaDDiR* and his Klown Krew surely never wanted you to see. They most certainly did not want CYDY longs to read any of these before tomorrow’s vote to grant the company an additional 200mm authorized shares, along with insane compensation for insiders.
For a start, how about this insane April 14, 2020, email from the the NaDDiR* to Amarex’s Kush Dhody, in which The NaDDiR, obsessed with the stock price and message board criticism, instructs his Krew to knowingly file an incomplete BLA:
And sure enough the something resembling a BLA was filed, and the company proudly (and falsely) announced that the completed BLA was submitted on the 27th of April:
As we all know, this was a lie. Just over one week later the company backtracked, but hid the disclosure in the boilerplate at the bottom of a press release. Finally, on May 11, they fessed up:
Surprising nobody, except the deluded retail longs who comprise the CYDY shareholder base, the FDA issued a Refusal To File (RTF) letter. For almost a year, The NaDDiR* has, himself, refused to divulge the contents of the letter. Originally The NaDDiR* claimed the issue was just the syringes. If that was true, why is the RTF letter 20 pages long? But today you can read it for yourself. Some choice tidbits:
Ooops. Did the company even file the BLA under the proper pathway? Last time anyone at BuyersStrike! HQ checked, biologics aren’t approved under 505(b)(1) or (2).
Sterility testing? We don’t need no testing because loserlimab “saveZ teH livEz” (at least according to the shills and morons who believe), plus sterility testing takes money away from stock promotion:
Did The NaDDiR* write the “Prescribing Information” section himself?
There is so much more to see in this letter, but don’t take our word for it. Read it for yourself.
* Spelled Thusly For A Double Dose of That Sweet Sweet Stock Pimping
THE CONTENT CONTAINED IN THIS BLOG REPRESENTS ONLY THE OPINIONS OF THE AUTHOR. THE AUTHOR MAY HOLD EITHER LONG OR SHORT POSITIONS IN SECURITIES OF VARIOUS COMPANIES DISCUSSED IN THE BLOG. THIS COMMENTARY IN NO WAY CONSTITUTES INVESTMENT ADVICE, AND SHOULD NEVER BE RELIED ON IN MAKING AN INVESTMENT DECISION, EVER. THIS BLOG IS NOT A SOLICITATION OF BUSINESS: ALL INQUIRIES WILL BE IGNORED. THE CONTENT HEREIN IS INTENDED SOLELY FOR THE ENTERTAINMENT OF THE READER, AND THE AUTHOR.